In the following video, Fool contributor Maxx Chatsko explains whether he thinks Celgene (CELG +0.00%) or Biogen (BIIB 0.13%) is the better buy. The companies have tracked one another in valuation, separated by as little as half of one percentage point. Additionally, both have promising pipelines that have kept investors' expectations high. Does one stand out? Is it too close to call? Watch the video below to find out. If you are eyeing either company -- or both -- then you may want to use the recent pullbacks as a buying opportunity.
Better Buy: Celgene or Biogen?
By Maxx Chatsko – Jun 25, 2013 at 10:45AM
NASDAQ: CELG
Celgene
Which biotech is the better buy?
About the Author
Maxx has been a contributor to Fool.com since 2013. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering.